In 2016, the World Health Organization (WHO) classifies BCR-ABL1-like ALL as a provisional entity of hematopoietic neoplasm with a lack of the BCR-ABL1 translocation (about 90%) but having a highly similar profile of gene expression to that seen in ALL with BCR-ABL1 (Ph+ ALL ) and also a high frequency of deletions of IKAROS family zinc finger 1 (IKZF1) [22]. The gene discussed is IKZF1; the disease is hematopoietic and lymphoid cell neoplasm.